DDInter489 DDInter1819
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Deferiprone {u} (Compound) binds {v} (Gene) UGT1A6
Deferiprone {u} (Compound) upregulates {v} (Gene) BTK
Deferiprone {u} (Compound) is included by {v} (Pharmacologic Class) Iron Chelating Activity
Deferiprone {u} (Compound) downregulates {v} (Gene) HSPA8
Deferiprone {u} (Compound) causes {v} (Side Effect) Rash pustular
Deferiprone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium sulfate
Deferiprone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Tioguanine
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Deferiprone (Compound) binds UGT1A6 (Gene)
Deferiprone (Compound) upregulates BTK (Gene)
Deferiprone (Compound) is included by Iron Chelating Activity (Pharmacologic Class)
Deferiprone (Compound) downregulates HSPA8 (Gene)
Deferiprone (Compound) causes Rash pustular (Side Effect)
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Deferiprone may lead to a major life threatening interaction when taken with Tioguanine
Deferiprone may lead to a major life threatening interaction when taken with Rucaparib